1. Home
  2. SNDX vs NTST Comparison

SNDX vs NTST Comparison

Compare SNDX & NTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • NTST
  • Stock Information
  • Founded
  • SNDX 2005
  • NTST 2019
  • Country
  • SNDX United States
  • NTST United States
  • Employees
  • SNDX N/A
  • NTST N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • NTST Real Estate Investment Trusts
  • Sector
  • SNDX Health Care
  • NTST Real Estate
  • Exchange
  • SNDX Nasdaq
  • NTST Nasdaq
  • Market Cap
  • SNDX 1.1B
  • NTST 1.3B
  • IPO Year
  • SNDX 2016
  • NTST 2020
  • Fundamental
  • Price
  • SNDX $10.70
  • NTST $16.15
  • Analyst Decision
  • SNDX Strong Buy
  • NTST Strong Buy
  • Analyst Count
  • SNDX 11
  • NTST 8
  • Target Price
  • SNDX $35.91
  • NTST $18.03
  • AVG Volume (30 Days)
  • SNDX 2.3M
  • NTST 929.2K
  • Earning Date
  • SNDX 05-05-2025
  • NTST 04-28-2025
  • Dividend Yield
  • SNDX N/A
  • NTST 5.20%
  • EPS Growth
  • SNDX N/A
  • NTST N/A
  • EPS
  • SNDX N/A
  • NTST N/A
  • Revenue
  • SNDX $43,722,000.00
  • NTST $171,021,000.00
  • Revenue This Year
  • SNDX $263.44
  • NTST $10.57
  • Revenue Next Year
  • SNDX $129.44
  • NTST $7.18
  • P/E Ratio
  • SNDX N/A
  • NTST N/A
  • Revenue Growth
  • SNDX N/A
  • NTST 22.05
  • 52 Week Low
  • SNDX $9.66
  • NTST $13.42
  • 52 Week High
  • SNDX $25.07
  • NTST $18.10
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.98
  • NTST 57.07
  • Support Level
  • SNDX $9.67
  • NTST $15.92
  • Resistance Level
  • SNDX $14.24
  • NTST $16.33
  • Average True Range (ATR)
  • SNDX 0.93
  • NTST 0.39
  • MACD
  • SNDX -0.26
  • NTST -0.02
  • Stochastic Oscillator
  • SNDX 22.62
  • NTST 66.95

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About NTST NetSTREIT Corp.

Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.

Share on Social Networks: